Oligosaccharide-dependent anti-inflammatory role of galectin-1 for macrophages in ulcerative colitis

J Gastroenterol Hepatol. 2020 Dec;35(12):2158-2169. doi: 10.1111/jgh.15097. Epub 2020 Jul 6.

Abstract

Background and aim: Galectin-1 plays a protective role against colitis by binding with polylactosamine structures on macrophages in β-1,4-galactosyltransferase I-deficient mice, but the precise function of galectin-1 remains unknown. In the present study, we investigated the anti-inflammatory role of galectin-1 on macrophages to ameliorate ulcerative colitis in both animal model and human tissue samples.

Methods: The expression of galectin-1 in colonic tissues of ulcerative colitis patients was evaluated by immunohistochemistry. Cytokine production of mouse bone marrow-derived macrophages (BMDMs) cultured with galectin-1 was investigated. Galectin-1 binding capacity and polylactosamine expression in macrophages stimulated with lipopolysaccharides were evaluated by flow cytometry. BMDMs cultured with galectin-1 were transferred into Recombination activating gene (Rag) 2-/- mice, and the severity of the dextran sodium sulfate-induced colitis model was investigated. Furthermore, RNA sequencing was performed to characterize macrophages treated with galectin-1.

Results: In ulcerative colitis patients, tissue expression of galectin-1was decreased in inflamed mucosa compared with non-inflamed mucosa. Galectin-1 induced interleukin-10 production in BMDMs, and the interleukin-10 production was abrogated by lactose, which inhibits the interaction of oligosaccharide-galectin binding. Dextran sodium sulfate colitis was significantly ameliorated in Rag2-/- mice undergoing galectin-1-treated BMDM transfer compared with those undergoing vehicle-treated BMDM transfer. RNA sequencing revealed that treatment with galectin-1 increased the expression of CCAAT/enhancer binding protein β and CD163, but decreased the expression of CD80 on BMDMs.

Conclusion: Galectin-1, whose expression is decreased in the inflamed mucosa of ulcerative colitis patients, can ameliorate murine colitis by conferring oligosaccharide-dependent anti-inflammatory properties to macrophages.

Keywords: Cebpβ; DSS-induced colitis; M2 macrophages; galectin-1; polylactosamine.

MeSH terms

  • Animals
  • Antigens, CD / genetics
  • Antigens, CD / metabolism
  • Antigens, Differentiation, Myelomonocytic / genetics
  • Antigens, Differentiation, Myelomonocytic / metabolism
  • B7-1 Antigen / genetics
  • B7-1 Antigen / metabolism
  • CCAAT-Enhancer-Binding Protein-beta / genetics
  • CCAAT-Enhancer-Binding Protein-beta / metabolism
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / genetics*
  • Disease Models, Animal
  • Galectin 1 / genetics
  • Galectin 1 / metabolism
  • Galectin 1 / physiology*
  • Galectin 1 / therapeutic use
  • Gene Expression*
  • Humans
  • Interleukin-10 / metabolism
  • Intestinal Mucosa / metabolism
  • Lactose / pharmacology
  • Macrophages / metabolism*
  • Macrophages / physiology*
  • Mice, Inbred C57BL
  • Oligosaccharides* / metabolism
  • Protein Binding
  • Receptors, Cell Surface / genetics
  • Receptors, Cell Surface / metabolism

Substances

  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • B7-1 Antigen
  • CCAAT-Enhancer-Binding Protein-beta
  • CD163 antigen
  • Galectin 1
  • Oligosaccharides
  • Receptors, Cell Surface
  • Interleukin-10
  • Lactose